While co‐treatment with MET did not affect Gck expression, G6pc was suppressed, potentially diminishing hepatic release of glucose and contributing to the MET‐mediated prevention of RAPA‐driven hyperglycemia. The gene discussed is GCK; the disease is Hyperglycemia.